Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SAN FRANCISCO and TEL AVIV, Israel, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX-V:KALY) (OTCQB:KALTF) (the "Company" or "Kalytera") today announced that the Company has...
-
SAN FRANCISCO and TEL AVIV, Israel, Jan. 11, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX-V:KALY) (OTCQB:KALTF) (the "Company" or "Kalytera") today announced that it has entered into an...
-
SAN FRANCISCO and TEL AVIV, Israel, Dec. 22, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (OTCQB:KALTF) (the "Company" or "Kalytera") today announced that the TSX Venture...
-
Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. SAN FRANCISCO...
-
SAN FRANCISCO and TEL AVIV, Israel, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX-V:KALY) and (OTCQB:KALTF) (the "Company" or "Kalytera") today announced the initiation of a...
-
SAN FRANCISCO and TEL AVIV, Israel, Dec. 05, 2017 (GLOBE NEWSWIRE) -- At the request of IIROC, Kalytera Therapeutics, Inc. (TSX-V:KALY) (OTCQB:KALTF) (the "Company" or "Kalytera") wishes to confirm...
-
/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/ SAN FRANCISCO and TEL AVIV, Israel, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE:KALY)...
-
SAN FRANCISCO, Calif. and TEL AVIV, Israel, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (OTCQB:KALTF), a clinical-stage pharmaceutical company developing...
-
SAN FRANCISCO and TEL AVIV, Israel, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY) (OTCQB:KALTF), a clinical-stage pharmaceutical company developing cannabinoid...
-
SAN FRANCISCO and TEL AVIV, Israel, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX-V:KALY) (OTCQB:KALTF), a clinical-stage pharmaceutical company developing cannabinoid...